Uppsala University Hospital and Elekta to further cancer research in Sweden

STOCKHOLM, July 10, 2014 – Uppsala University Hospital (UUH) and Elekta today
announced that they have signed an agreement to jointly work at the forefront of
imaging in cancer care research.

With this research agreement, Uppsala University Hospital and Elekta seek to
contribute to the field of personalized care by using Magnetic Resonance Imaging
(MRI) and Positron Emission Tomography (PET).

In the future MRI potentially enables doctors to treat cancer with radiation
while seeing in real time where the tumor is and correct for movement. This is
limited with imaging used today.

Elekta, Philips and some of the most renowned universities in the world have
started to do research into integrating MRI with linear accelerators. This
research is still at its early stages, but is attracting interest from
oncologists all over the world.

With this joint research agreement Uppsala intends to become the first hospital
in Sweden to receive a clinical system, once it has been approved by the
regulatory authorities (CE-mark). To prepare for this, UUH has already started
the building of new facilities, with bunkers that are capable of receiving such
treatment units of the future.

Kristina Nilsson, MD, PhD at Uppsala University Hospital commented: “We envision
that by using integrated MRI, in planning and implementation of radiation
therapy, future therapy will become more precise and better adjusted to both the
tumor and to nearby tissues, sensitive to radiation.”

Elekta CEO Niklas Savander said: “We are convinced that combining radiation
therapy with MRI shall play a prominent role in the future of cancer care.
Elekta is proud that Uppsala University Hospital will become a research partner
in Sweden, helping us develop the clinical approach to introducing such new
techniques for the benefit of patients.”

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 08:00 CET on July 10, 2014.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO:EKTAB. Website:
www.elekta.com.